Neoplasms

All Conditions

Symptoms and General Pathology

Nervous System Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma

Recurrence

Brain Neoplasms

Nasopharyngeal Carcinoma

Wilms Tumor

Fibrosarcoma

Nasopharyngeal Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Neoplasms, Glandular and Epithelial

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Sarcoma

Wilms' Tumor

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Carboplatin

Thiotepa

Myeloablative Chemotherapy, followed by stem cell rescue

High dose chemotherapy (carboplatin and thiotepa) transplant rescue

Myeloablative Chemotherapy

Stem Cell Rescue

John E. Levine, MS MD

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

This is a phase II trial designed to provide a transplant option for patients with rare poor-prognosis cancers. The protocol is only open to patients with metastatic or relapsed cancers for whom the probability of remaining free of progressive disease for one year after being brought into remission is \< 25%. Patients eligible for this study have been diagnosed with a form of cancer that leads to death more than 75% of the time when treated with standard therapy doses of chemotherapy and/ or radiation therapy. Under this treatment intensification protocol the expectation is that the one year progression-free survival for this group of patients will rise to 40%. Patients eligible for this protocol will be followed for one year post-transplant. Patients alive and free of progressive disease at the end of this period will be considered successes.

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers

The primary outcome measure for this study was to improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse.

University of Michigan Rogel Cancer Center

Professor of Pediatrics and of Internal Medicine

Myeloablative Chemotherapy: High dose chemotherapy (carboplatin and thiotepa) transplant rescue

Stem Cell Rescue: autologous stem cell transplantation

Spots Global Cancer Trial Database for stem cell rescue